Hemostemix to Attend DFCon San Antonio and Closed its Private Placement

Executive Summary

• Hemostemix announced participation in DFCon 2025, a major diabetic foot care conference, highlighting Phase II clinical trial results for its VesCell™ (ACP‑01) therapy.
• The TSX Venture Exchange approved a non‑brokered private placement of $518,440 for 520,090 units at $0.11 per unit, each unit consisting of one common share and one warrant to purchase an additional share at $0.15 for two years (with accelerated expiry provisions).
• Clinical data presented show a statistically significant reduction in ulcer size and lower amputation/death rates versus placebo, supporting the commercial potential of VesCell™.

Key Details

• Conference Participation
• Hemostemix will exhibit at DFCon 2025 in San Antonio, Texas (Friday‑Sunday), engaging clinicians and researchers on ACP‑01 outcomes.

• CEO Thomas Smeenk highlighted Phase II results: 83% limb preservation, ulcer size reduction from 146 mm² to 0.48 mm² (p = 0.01) at 3 months for treated patients versus no significant change in placebo.

• Financing – Private Placement

• Total gross proceeds: $518,440.
• Units offered: 520,090, each at $0.11 per unit.
• Composition of each Unit:
  • 1 common share.
  • 1 common share purchase warrant (right to acquire one additional common share at $0.15 per share for two years from closing).
• Accelerated expiry clause: If, after four months + 1 day, the TSX‑V exchange price exceeds a weighted average of $0.185 for ten consecutive trading days, the company may accelerate warrant expiry to 30 days after a press release.

• This placement adds to a previously announced closing of 4,193,000 units.

• Clinical Highlights (Phase II)

• Study size: 21 treated vs. 8 placebo subjects.
• Mortality: 0% in treated group vs. 12.5% in placebo.
• Amputation rate: 4.8% (treated) vs. 25% (placebo).
• Ulcer size reduction (treated): mean from 146 mm² to 0.48 mm² (p = 0.01) by three months.

• No significant ulcer size change in placebo (p > 0.54).

• Forward‑Looking Statements

• Company references ongoing Phase I trials for vascular dementia and further commercialization efforts, including compassionate use under Florida SB 1768.

Notable Quotes

• “VesCell saves diabetic limbs from amputation, and that saves lives,” – Thomas Smeenk, CEO.

Materiality Assessment: Material – Positive (significant financing to fund operations and clinically meaningful trial results supporting product commercialization).